重症急性胰腺炎免疫调节治疗的研究进展  

Progresses of immunomodulatory therapy in sever acute pancreatitis

作　　者：贺光明[1] 熊冠泽[1] 卢松[1] 徐珊玲[1] 陈珂玲[2] He Guangming Xiong Guanze Lu Song Xu Shanling Chen Keling(Department of Critical Care Medicine, Sichuan Cancer Hospital, Chengdu 610041, Sichuan, China Institute of Digestive Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, Chin)

机构地区：[1]四川省肿瘤医院重症医学科,四川成都610041 [2]四川大学华西医院消化外科研究室,四川成都610041

出　　处：《中华危重病急救医学》2017年第10期954-957,共4页Chinese Critical Care Medicine

基　　金：国家自然科学基金（81500486）

摘　　要：重症急性胰腺炎（SAP）病程复杂,预后凶险.免疫应答失衡是导致胰腺炎患者转向重症甚至死亡的重要原因.免疫调节治疗可调控机体失衡的炎症反应,减轻SAP相关器官损伤,改善患者预后.早期免疫调节措施存在对象单一、方式简单等问题.近年来新出现的治疗方式,如调节免疫细胞成熟与凋亡、应用间充质干细胞（MSCs）及多因素联合治疗等,为未来SAP的治疗提供了新的思路和希望.本文就SAP免疫调节的发展及近年来的新进展进行综述.Severe acute pancreatitis （SAP） is accompanied with complex pathogenic course and high mortality. The imbalance of immune response is an important cause which leads the SAP patients to the severe situation and even death. The immunomodulatory therapy can regulate the imbalance of inflammation, alleviate SAP-associated organ injury, and improve the prognosis of patients. Previous immunomodulatory therapy had some problems, such as single-object and simple-method. In recent years, some new methods of immunomodulatory therapy, such as regulating the apoptosis and mature of immune cells, applying of mesenchymal stem cells （MSCs） and multi-regulation methods, provide some new ideas and hopes for SAP therapy. This paper reviewed the history and recent research progresses of SAP immunomodulatory therapy.

关 键 词：胰腺炎 急性 重症 免疫应答 免疫调节 炎症反应 

分 类 号：R576[医药卫生—消化系统]